CPT-11 (Irinotecan), Oxaliplatin and Xeloda (COX) in Patients with Advanced Colorectal Cancer

Official Title

A Phase I/II Study of CPT-11 (Irinotecan), Oxaliplatin and Xeloda (COX) in Patients with Advanced Colorectal Cancer


Triplets of I, O and infusional 5-FU/leucovorin (LV) are associated with high response rates and long survival as first-line treatment for MCRC. The oral fluoropyrimidine X (Xeloda®) is better tolerated and shows better response rates than 5-FU/LV in MCRC. This dose-escalation study aims to establish doselimiting toxicity (DLT), maximum tolerated dose (MTD) and recommended phase II doses (RPIID) of I, O and X and to evaluate efficacy and safety in the first-line setting.

Trial Description

Primary Outcomes

  • To determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and the recommended dose (RD) for phase II studies of COX in patients with unresectable advanced and/or metastatic colorectal cancer.

Secondary Outcomes

  • To determine the toxicity of COX and define duration and reversibility of these toxicity.
  • To assess clinical response rates of the combination.Identify the intended trial objectives, including the time(s) at which the outcomes will be measured

This is a non-randomized, open label, phase I/II trial. The design of the study is a dose-finding phase I type to determine the recommended doses of oxaliplatin followed by irinotecan on day 1 and oral xeloda given orally on days 2-15, every 3 weeks. The phase I portion will be followed by a phase II part at the recommended dose levels for the triplet.

Originally registered on March 28, 2007.

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society